Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 14, 2026
TickeronGET DAILY SIGNALS
Palisade Bio (PALI): Analyst Targets Suggest +614% Upside From Current Levels

Palisade Bio (PALI): Analyst Targets Suggest +614% Upside From Current Levels

Key Takeaways

  • The central price target used here is $8, the arithmetic mean of nine verified, individually attributed analyst price targets, rounded to the nearest dollar.
  • With Palisade Bio, Inc. (PALI) last trading near $1.12, reaching $8 would require a roughly 614% gain — a very large move for any stock.
  • Individual analyst targets span a wide range from $5 to $16, reflecting deep disagreement about the value of the company's lead drug candidate, PALI-2108.
  • The strongest support comes from promising Phase 1b data in fibrostenotic Crohn's disease and a Phase 2a ulcerative colitis trial expected to begin in early 2027.
  • The biggest risks are that Palisade Bio is pre-revenue, is losing money, trades near its 52-week low, and has no late-stage efficacy data yet.
  • For more context, visit Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
  • Explore Trending AI Robots to see AI-driven trading strategies applied across thousands of stocks and ETFs.

Breaking Down the Analyst Targets

Palisade Bio is a Denver-based, clinical-stage biopharmaceutical company developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs for inflammatory bowel disease. It is a stock, not an ETF, so its price target is derived from analyst research rather than fund holdings or flows.

Reviewing recent, individually attributed targets yields nine usable figures: Piper Sandler at $16 (November 11, 2026), Clear Street at $12, Oppenheimer at $8, Maxim Group at $8, B. Riley Securities at $7, Wolfe Research at $7, Raymond James at $6, H.C. Wainwright at $5, and Stifel at $5. The simple average is about $8.20, which rounds to a central target of $8. This is not an official published consensus; reputable aggregators currently report slightly different averages because of timing and methodology differences.

The $5-to-$16 range is unusually wide, underscoring how much analyst opinions diverge. Most firms rate the stock Buy or Outperform, but recent actions have been cautious in direction. In November 2026, Piper Sandler cut its target from $25 to $16 and H.C. Wainwright cut from $7 to $5, even as both kept positive ratings. The general analyst rationale is that PALI-2108's early data supports meaningful upside, but the stock's price reflects deep skepticism about a pre-revenue biotech with distant data readouts. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

Palisade Bio shares closed near $1.12 in mid-November 2026, near the low end of a 52-week range of roughly $1.08 to $2.86. A move to $8 would represent an increase of about 614% — a very large move by any standard, and one that would require the stock to exceed its recent 52-week high more than two-and-a-half times over.

The path to such a level runs almost entirely through clinical execution. The company's lead candidate, PALI-2108, has reported Phase 1b data in fibrostenotic Crohn's disease showing 40% endoscopic remission and 40% endoscopic response. The next major milestone is the open-label Phase 2a ASCENTRA-CD trial, expected to begin in the first quarter of 2027, with a potential interim readout in the second half of 2027 and a primary efficacy readout in early 2028.

What Could Support a Move Toward the Target

Positive, de-risking clinical data is the central bull case. Analysts including Piper Sandler have argued the market under-appreciates PALI-2108's catalyst path, and that Phase 1b results help de-risk the larger Phase 2a trial. The company also reported roughly $133 million in cash as of early 2026, which may fund operations through near-term catalysts. Broader sentiment toward innovative inflammatory bowel disease therapies and any partnership or licensing activity could add further support.

What Could Prevent the Target From Being Reached

The risks are substantial. Palisade Bio is pre-revenue and consistently unprofitable, posting a quarterly loss of $0.07 per share in its most recent report, slightly worse than the $0.06 consensus estimate. Its value depends almost entirely on PALI-2108, and any clinical setback, delay, or dilution from future equity raises could pressure the stock. The shares have declined sharply over the past year and sit near their 52-week low, indicating that the market currently assigns little credit to the bullish analyst targets.

Technical Levels and Market Structure

The stock's price action is weak. Shares trade below their 50-day and 200-day moving averages and near the 52-week low around $1.08, which is the most relevant nearby support level. On the upside, the prior 52-week high near $2.86 and round psychological levels in the low single digits represent meaningful resistance. The wide gap between the current price and even the lowest analyst target reflects a market that is pricing the stock primarily on execution risk rather than on projected value.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms may apply different assumptions. The most important items to watch are the initiation and enrollment of the ASCENTRA-CD Phase 2a trial, any interim efficacy data, further analyst target revisions, quarterly cash-burn updates, and any financing or partnership announcements. Earnings guidance matters less for a pre-revenue biotech, but cash runway and trial timelines are critical.

Using AI Tools for Deeper Analysis

In my view, tools like Tickeron’s AI Trend Prediction Engine can help investors track technical patterns and sentiment shifts in volatile names like this one, providing an additional layer of insight alongside traditional research. From what I see, combining these signals with clinical timelines gives a clearer picture of potential inflection points without replacing fundamental due diligence.

Final Assessment

Can Palisade Bio reach $8? The $8 central target is the rounded average of nine analyst targets spanning $5 to $16, and it implies a move of roughly 614% from the current price near $1.12 — an extraordinarily large gap that reflects both the promise of PALI-2108 and the market's profound skepticism. Support rests on early clinical data and upcoming trial catalysts, while the principal obstacles are the company's pre-revenue status, ongoing losses, and a stock trading near its 52-week low. The targets are not a guarantee, and the wide analyst range shows that even bullish firms disagree sharply on magnitude. Investors should monitor clinical milestones and cash runway above all.

Exploring Tickeron AI Tools

I’ve found Tickeron’s AI Daily Buy/Sell Signals particularly useful for monitoring stocks like Palisade Bio. The platform applies artificial intelligence to scan thousands of securities in real time, generating signals based on technical and market changes. This can streamline the process of spotting shifts in trend or volatility, especially for a clinical-stage name driven by upcoming data readouts. It serves as one more resource alongside analyst reports and trial updates.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PALI

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for PALI turns negative, indicating new downward trend

PALI saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In 90 of the 95 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PALI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for PALI entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PALI's RSI Indicator exited the oversold zone, 34 of 38 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for PALI just turned positive on November 04, 2026. Looking at past instances where PALI's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.

Following a +11.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where PALI advanced for three days, in 168 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

PALI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.618) is normal, around the industry mean (3.498). P/E Ratio (1.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. PALI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PALI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds

Industry Biotechnology

Industry
N/A
Address
4600 South Syracuse Street
Phone
+1 858 704-4900
Employees
14
Web
https://www.palisadebio.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
LITE is the Nasdaq-listed ticker for Lumentum Holdings Inc., a global manufacturer of optical and photonic products used in data centers, AI infrastructure, and telecommunications networks. The company was spun off from JDS Uniphase and incorporated in 2015, with headquarters in San Jose, California.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.